Becton Dickinson stock trades below analyst targets as investors weigh recent guidance
Published on 09/11/2026 at 22:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Becton, Dickinson and Company stock (ISIN US0718131099) last closed at USD 176.42 on the New York Stock Exchange on September 10, 2026, leaving the shares below the average analyst price target near USD 187.67 according to recent data. As of September 11, 2026, consensus forecasts for the current fiscal year point to revenue of around USD 19.55 billion, highlighting the growth expectations embedded in the valuation per figures compiled by Forbes.
Analyst consensus and valuation levels
Recent analyst overviews show that Becton Dickinson stock carries a consensus rating of Hold, with an average price target of USD 187.67 based on coverage from 17 analysts, implying upside of about 6.5 percent from the latest close at USD 176.42 according to MarketBeat. Individual targets range from USD 150.00 on the cautious side to USD 210.00 on the optimistic end, underscoring differing views on the company’s earnings trajectory and balance sheet strength as summarized by Forbes. For investors, this spread between the current share price and the average target has become a key reference point when assessing risk and reward.
Consensus earnings expectations provide further context. According to data presented by Forbes, analysts currently project earnings per share of about USD 13.24 for the ongoing fiscal year, within a range of roughly USD 12.87 to USD 14.04. With revenue consensus at approximately USD 19.55 billion, the implied profit expectations point to a business that is still expanding while managing investments in diagnostic and medical device platforms.
Price performance and technical context
Becton Dickinson’s recent trading history shows how the stock has moved in early September. Price tables compiled by Forbes indicate that on September 10, 2026, the shares opened and reached an intraday high at USD 178.94 before closing at USD 176.42, with a trading volume of about 1,671,771 shares. On September 9, 2026, the stock closed higher at USD 179.80 after trading between USD 176.55 and USD 182.10, illustrating that the current level is slightly below the short-term peaks hit earlier in the month.
Over a longer horizon, investors often look at the 52-week range to gauge where the current price sits in historical context. As of September 11, 2026, an overview on MarketBeat lists a 52-week low of USD 127.59 and a 52-week high of USD 193.07 for Becton Dickinson shares. With the latest close at USD 176.42, the stock is trading closer to the upper end of this range than to the low, but still about 8.6 percent below the 52-week high and considerably above the lows seen over the past year. MarketBeat also reports a market capitalization of about USD 48.54 billion as of early September 2026, reflecting the size of the company in the global medical technology sector.
Guidance, risks and investor focus
While detailed quarterly figures and margins must be taken from the company’s formal filings, current consensus revenue expectations of USD 19.55 billion for the fiscal year frame the market’s view of Becton Dickinson’s growth profile, as highlighted in the analyst summary on Forbes. Against this, investors are watching execution risks in areas such as product launches, regulatory approvals and cost control, which could cause results to deviate from the projected earnings per share range of USD 12.87 to USD 14.04 for the year.
Analyst commentaries also emphasize that, with a consensus rating of Hold and targets clustered around USD 185 to USD 195, Becton Dickinson stock is viewed as offering more modest upside compared with higher-growth healthcare names, even though its dividend yield of around 2.38 percent adds an income component according to MarketBeat. For shareholders, the balance between steady cash flows, the dividend and limited price upside is central to the investment case at the current valuation.
Stock level and trading venue
On its primary listing at the New York Stock Exchange under the ticker BDX, Becton Dickinson stock therefore stands at USD 176.42 based on the closing price of September 10, 2026, in United States dollars. With the 52-week range stretching from USD 127.59 to USD 193.07 and a market capitalization of about USD 48.54 billion as of early September 2026, the share price currently reflects a position below the average analyst target but still near the upper half of its annual trading band.
Becton Dickinson stock at a glance
- Company: Becton, Dickinson and Company
- ISIN: US0718131099
- Ticker: BDX
- Trading venue: NYSE
- Price (as of September 10, 2026): 176.42 USD
- Market capitalization: 48.54 billion USD (as of September 11, 2026)
- Sector / Industry: Health Care / Medical Technology
- Index membership: S&P 500
